undamentalytics Newsletter
Sign in

Ardelyx, Inc. balance sheet

At the end of fiscal 2025, Ardelyx, Inc. had total assets of $502m, total liabilities of $335m and shareholders' equity of $167m. It held $68.0m in cash against $203m of debt: net debt of $135m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents3334107107757918191729621656897
Receivables—63————018225872100
Inventory————————0284991123139
Total current assets—421111125176252195134154246356382442
Total assets—43113117158183260202150190298436502576
Accounts payable—233412641111161938
Deferred revenue (current)—1416——1—40471117
Total current liabilities—1722811822285366507889132
Short-term debt————————32—————
Long-term debt—————525051322750151203252
Total debt00000525252332952151203252
Total liabilities—50538196873756792131262335427
Shareholders' equity−57−63611091391161871268398167173167149
Non-controlling interests and other (assets − liabilities − equity)—56————————————
Net debt (negative = net cash)−33−34−107−107−75−27−129−39−39−673186135155
Shares outstanding—2m19m—48m63m—94m130m—232m238m244m249m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ARDX vs CRMDARDX vs ARQTARDX vs KRYS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ardelyx, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ardelyx, Inc.